Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/legend-biotech-corp">Legend Biotech Corp</a>oration (NASDAQ: LEGN) reached a historic financial inflection point in Q2 2026 by achieving company-wide GAAP operating profitability (15% operating margin, $33.25 million net income), driven by global CARVYKTI net trade sales surging 50% year-over-year to approximately $657 million.</li>
  <li>Commercial expansion of CARVYKTI (ciltacabtagene autoleucel), co-developed and commercialized under a 50/50 worldwide profit-split with Johnson &amp; Johnson, continues to strengthen via label expansion into 2nd-to-4th line multiple myeloma (CARTITUDE-4) and unparalleled long-term durability data (CARTITUDE-2 5-year progression-free survival rate of 50%).</li>
  <li>At a last price of $19.04, Legend trades at an attractive enterprise value to sales multiple of ~2.4x annualized run-rate revenue, backed by $965 million in cash and short-term investments, providing an asymmetric risk-reward profile as the market discounts recent CEO leadership succession and pipeline execution toward in vivo CAR-T (LB2501).</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Legend Biotech Corporation (NASDAQ: LEGN) reached a historic financial inflection point in Q2 2026 by achieving company-wide GAAP operating profitability (15% operating margin, $33.25 million net income), driven by global CARVYKTI net trade sales surging 50% year-over-year to approximately $657 million.
  Commercial expansion of CARVYKTI (ciltacabtagene autoleucel), co-developed and commercialized under a 50/50 worldwide profit-split with Johnson &amp; Johnson, continues to strengthen via label expansion into 2nd-to-4th line multiple myeloma (CARTITUDE-4) and unparalleled long-term durability data (CARTITUDE-2 5-year progression-free survival rate of 50%).
  At a last price of $19.04, Legend trades at an attractive enterprise value to sales multiple of ~2.4x annualized run-rate revenue, backed by $965 million in cash and short-term investments, providing an asymmetric risk-reward profile as the market discounts recent CEO leadership succession and pipeline execution toward in vivo CAR-T (LB2501).
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Legend Biotech Corp (LEGN US) - Oct 2026

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Legend Biotech reported second-quarter 2026 results showing continued commercial and clinical growth alongside a leadership transition.</li><li>Following the former CEO’s departure, Alan Bash was appointed Interim CEO.</li><li>Management emphasized continuity around maximizing CARVYKTI, advancing the next-generation pipeline, and maintaining operational discipline.</li></ul>

Legend Biotech reported second-quarter 2026 results showing continued commercial and clinical growth alongside a leadership transition.Following the former CEO’s departure, Alan Bash was appointed Interim CEO.Management emphasized continuity around maximizing CARVYKTI, advancing the next-generation pipeline, and maintaining operational discipline.

Legend Biotech's Pivotal Transition — CARVYKTI Momentum Meets a New Leadership Era!

Healthcare Analyst

Wilfred Yuen

<ul>
<li>2Q26 profitability on track, with Carvykti sales up 50% YoY and operating margin of 15%. 1Q26 marks Legend’s first quarter of company-wide profitability on both IFRS and adjusted basis</li>
<li>LEGN 2H26 catalysts: 1) continued QoQ Carvykti growth (growing portion from 2-4L patients); 2) adjusted net income profitability; 3) IND submission for LB2501 (4Q26); 4) presenting additional in vivo data</li>
<li>See inside for 2Q26 results call takeaways, management financial outlook/guidance, and LEGN quarterly P&amp;L analysis</li>
</ul>


2Q26 profitability on track, with Carvykti sales up 50% YoY and operating margin of 15%. 1Q26 marks Legend’s first quarter of company-wide profitability on both IFRS and adjusted basis
LEGN 2H26 catalysts: 1) continued QoQ Carvykti growth (growing portion from 2-4L patients); 2) adjusted net income profitability; 3) IND submission for LB2501 (4Q26); 4) presenting additional in vivo data
See inside for 2Q26 results call takeaways, management financial outlook/guidance, and LEGN quarterly P&amp;L analysis


LEGN: 2Q26 Call Takeaways; 2026 Profitability on Track; Next up on LB2501 (In Vivo CAR-T) Updates

Thematic (Sector/Industry)

<ul>
<li>We highlight key updates from October's ESMO meeting: 1) Akeso's ivonescimab in 1L BTC, 2) Kelun/Merck's sac-TMT (Lung04, Lung06, TroFuse-005), 3) Hutchmed/AZ's savo, 4) Hansoh/GSK's B7H3 ADC, 5) Innovent IBI363...</li>
<li>BD deal flows this week: 1) Innocare/Lilly on 5-target drug discovery, 2) Earendil Labs/Genentech on bispecific, 3) Insilico Medicine/AI frontier model lab, 4) BoomRay/Novartis on radioligand, 4) Henlius/Amberstone on TCE</li>
<li>Other updates/news: 1) LEGN's 5-year Carvykti OS data in Cart-2 study, 2) BeOne's first-in-class GPC3/4-1BB entering ph3 study in HCC, 3) TYK/Qilu deal update...</li>
</ul>


We highlight key updates from October's ESMO meeting: 1) Akeso's ivonescimab in 1L BTC, 2) Kelun/Merck's sac-TMT (Lung04, Lung06, TroFuse-005), 3) Hutchmed/AZ's savo, 4) Hansoh/GSK's B7H3 ADC, 5) Innovent IBI363...
BD deal flows this week: 1) Innocare/Lilly on 5-target drug discovery, 2) Earendil Labs/Genentech on bispecific, 3) Insilico Medicine/AI frontier model lab, 4) BoomRay/Novartis on radioligand, 4) Henlius/Amberstone on TCE
Other updates/news: 1) LEGN's 5-year Carvykti OS data in Cart-2 study, 2) BeOne's first-in-class GPC3/4-1BB entering ph3 study in HCC, 3) TYK/Qilu deal update...


<ul><li>Legend Biotech reported its first quarter of 2026 financial and operational results marked by continued commercial expansion of its lead product, CARVYKTI, and advancing development of its broader pipeline, including several in vivo CAR-T therapy programs.</li><li>During the quarter, CARVYKTI generated approximately $597 million in net trade sales, representing a 52% year-over-year increase.</li><li>Growth drivers included a 36% increase in U.S. sales and over 200% growth internationally, with availability now expanded across 18 markets and more than 300 treatment sites globally.</li></ul>

Legend Biotech reported its first quarter of 2026 financial and operational results marked by continued commercial expansion of its lead product, CARVYKTI, and advancing development of its broader pipeline, including several in vivo CAR-T therapy programs.During the quarter, CARVYKTI generated approximately $597 million in net trade sales, representing a 52% year-over-year increase.Growth drivers included a 36% increase in U.S. sales and over 200% growth internationally, with availability now expanded across 18 markets and more than 300 treatment sites globally.

Legend Biotech's In Vivo CAR-T Pipeline: Could BCMA And GPRC5D Reset The Story?

China

Legend Biotech Corporation operates as a biopharmaceutical company. The Company engages in discovery and development of novel cell therapies for oncology and other indications. Legend Biotech serves customers in the State of New Jersey.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Legend Biotech Corp (LEGN US)

Primer: Legend Biotech Corp (LEGN US) - Oct 2026

Legend Biotech Corporation (NASDAQ: LEGN) reached a historic financial inflection point in Q2 2026 by achieving company-wide GAAP operating...

αSK Primers

Legend Biotech's Pivotal Transition — CARVYKTI Momentum Meets a New Leadership Era!

Legend Biotech reported second-quarter 2026 results showing continued commercial and clinical growth alongside a leadership transition. Following...

Baptista Research

LEGN: 2Q26 Call Takeaways; 2026 Profitability on Track; Next up on LB2501 (In Vivo CAR-T) Updates

2Q26 profitability on track, with Carvykti sales up 50% YoY and operating margin of 15%; LEGN 2H26 key catalysts: continued QoQ Carvykti growth +...

Wilfred Yuen

China Healthcare Weekly Wrap (21-25 Sep)

We highlight 1) key studies to watch for upcoming October's ESMO updates, 2) deal flows Innocare/Lilly, BoomRay/Novartis, Earendil Labs...

Wilfred Yuen

Legend Biotech's In Vivo CAR-T Pipeline: Could BCMA And GPRC5D Reset The Story?

Legend Biotech reported its first quarter of 2026 financial and operational results marked by continued commercial expansion of its lead product,...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)